These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 30045621)
1. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. He S; Dong G; Wu S; Fang K; Miao Z; Wang W; Sheng C J Med Chem; 2018 Aug; 61(16):7245-7260. PubMed ID: 30045621 [TBL] [Abstract][Full Text] [Related]
2. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway. Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model. Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237 [TBL] [Abstract][Full Text] [Related]
4. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248 [TBL] [Abstract][Full Text] [Related]
5. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148 [TBL] [Abstract][Full Text] [Related]
6. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres. Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644 [TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699 [TBL] [Abstract][Full Text] [Related]
8. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118 [TBL] [Abstract][Full Text] [Related]
9. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction. Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609 [TBL] [Abstract][Full Text] [Related]
10. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors. Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors. Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354 [TBL] [Abstract][Full Text] [Related]
13. Rational design and binding mode duality of MDM2-p53 inhibitors. Gonzalez-Lopez de Turiso F; Sun D; Rew Y; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Correll TL; Huang X; Julian LD; Kayser F; Lo MC; Long AM; McMinn D; Oliner JD; Osgood T; Powers JP; Saiki AY; Schneider S; Shaffer P; Xiao SH; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH J Med Chem; 2013 May; 56(10):4053-70. PubMed ID: 23597064 [TBL] [Abstract][Full Text] [Related]
14. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel inhibitors of the MDM2-p53 interaction. Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527 [TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction. Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253 [TBL] [Abstract][Full Text] [Related]
17. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction. Beloglazkina A; Zyk N; Majouga A; Beloglazkina E Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275 [TBL] [Abstract][Full Text] [Related]
19. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834 [TBL] [Abstract][Full Text] [Related]
20. Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor. Miyazaki M; Uoto K; Sugimoto Y; Naito H; Yoshida K; Okayama T; Kawato H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T Bioorg Med Chem; 2015 May; 23(10):2360-7. PubMed ID: 25882531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]